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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction and airway inflammation (Barnes, 2003) . Alveolar macrophages (AM) are believed to play a central role in disease pathogenesis by secreting proinflammatory cytokines and chemokines (Barnes, 2003) . Glucocorticoids (GC) are the most widely used anti-inflammatory therapy in COPD. GC suppress inflammatory gene transcription by forming a complex with the glucocorticoid receptor (GR) that inhibits the function of transcription factors such as nuclear factor (NF)-κB, a process known as transrepression (Glass and Ogawa, 2006) . However, the clinical benefits of GC in COPD patients are modest (Soriano et al., 2007) , and the suppression of cytokine production from COPD AM is reported to be GC resistant (Cosio et al., 2004; Culpitt et al., 2003) . Alternative anti-inflammatory therapies are needed in COPD (Barnes, 2006) . Extra-cellular stimuli such as the TOLL-like receptor (TLR) 4 ligand lipopolysacharide (LPS) and cytokines activate p38 mitogen activated protein kinase (MAPK) intracellular signalling. This signalling pathway up-regulates the production of pro-inflammatory cytokines and chemokines (Zarubin and Han, 2005) through the activation of transcription factors such as NFκB and ATF2 or alterations in chromatin structure to allow NFκB binding to the promoter regions of inflammatory genes (Saccani et al., 2002) . p38 MAPK may also act post-transcriptionally through mRNA stabilisation (Winzen et al., 1999) , or at the level of protein translation (Brook et al., 2006; Newton and Holden, 2003) . Activated p38 MAPK expression is increased in pulmonary macrophages from COPD patients (Renda et al., 2008) , implicating this signalling pathway in the pathophysiology of COPD. p38 MAPK inhibitors are This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 12, 2008 as DOI: 10.1124 at ASPET Journals on November 5, 2017 jpet.aspetjournals.org Downloaded from therefore in clinical development for the treatment of COPD (Barnes, 2006) . In THP-1 cells and healthy human AM, the p38 MAPK inhibitors SB203850 and "compound 2" inhibited LPS stimulated cytokine protein levels, but with little or no effect on cytokine mRNA levels (Birrell et al., 2006) . This suggests that these p38 MAPK inhibitors act at the level of protein translation rather than gene transcription in macrophages.
GCs inhibit p38 MAPK activity by increasing the gene expression of MAPK phosphatase-1 (Lasa et al., 2002) . Additionally, p38 MAPK inhibitors may enhance the effects of GC (Irusen et al., 2002) by altering the phosphorylation of the GR (Szatmary et al., 2004) . These potentially synergistic interactions provide a good rationale to use these two classes of drug together to maximise anti-inflammatory effects.
In AM from controls and patients with emphysema the p38 MAPK inhibitors SB239063 and SD-282 significantly inhibited LPS induced tumour necrosis factor (TNF)-α protein levels, but had little effect on interleukin (IL)-8 (also known as CXCL8) and granulocyte macrophage colony stimulating factor (GM-CSF), indicating that the effects of p38 MAPK inhibitors varies between inflammatory genes (Smith et al., 2006) . Similarly, ligand activated GR does not target all inflammatory genes, but represses the activity of the subset of inflammatory genes that have GR dependent transcriptional activation (Glass and Ogawa, 2006) . This phenomenon is cell type specific, and is dependent on the type of stimulus used (Ogawa et al., 2005) .
It would be of importance to evaluate and compare the sensitivity to GC and p38 MAPK inhibitors of inflammatory genes in COPD macrophages.
The p38 pyrimidin-2-yl]amino}ethyl)guanidine, This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 12, 2008 as DOI: 10.1124 at ASPET Journals on November 5, 2017 jpet.aspetjournals.org Downloaded from also known as PCG, has high specificity for the α and β p38 MAPK isoforms, and low activity against other kinases (Tudhope et al., 2008) . This novel MAPK inhibitor has been shown to reduce TNFα, GMCSF and IL-6 production from LPS stimulated COPD macrophages, with less effect on IL-8 production supporting previous data that some inflammatory cytokines are less sensitive to p38 MAPK inhibitors (Smith et al., 2006) . We wanted to extend this observation further, to profile a range of inflammatory genes to identify p38 MAPK sensitive and insensitive genes.
Furthermore, we were interested to understand the effects of this drug at the levels of gene transcription, and when used with a glucocorticoid.
This paper reports the effects of the GC dexamethasone and SB706504 on LPS activation of inflammatory genes in macrophages from COPD patients. We used monocyte derived macrophages (MDMs) from COPD patients to perform gene array studies with the following aims; (1) to determine whether SB706504 suppressed the transcription of inflammatory genes (2) to identify LPS activated inflammatory genes that were insensitive to SB706504 or dexamethasone. We also studied the effects of combined treatment with SB706504 and dexamethasone. Quantitative PCR and protein analysis were performed to confirm gene array findings. Finally, we present experiments using LPS stimulated AM from COPD patients, and a control group of healthy smokers, evaluating the effects of combined treatment with SB706504 and dexamethasone.
This article has not been copyedited and formatted. The final version may differ from this version. Former smokers were defined on the basis of stopping smoking for at least 1 year.
Demographics for all patients used in this study are provided in Table 1 . The local research ethics committee approved this study and written informed consent for each patient was obtained.
MDM Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood as described previously (Kent et al., 2008; Stengel et al., 1998) . These cultures have previously been shown to consist of entirely CD68+ macrophages (Stengel et al., 1998) , and we obtained similar data in MDMs from 3 subjects using flow cytometry (data not shown). Media was removed from MDMs prior to addition of drugs (1ml/well); 100nM dexamethasone (Cat No. D8893, Sigma-Aldrich) and/or 3µM SB706504 (gift from GlaxoSmithKline, UK) previously stored in DMSO. This concentration was chosen based on previous data (Tudhope et al., 2008) showing that the maximal effect of this compound on p38 activation was reached at 10µM. Cells
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Transcriptomic Analysis
RNA Isolation and Microarray Analysis
Cells were lysed in Trizol (Invitrogen, Paisley, UK) and protocols for RNA isolation, quantification and quality assessment, and Affymetrix microarray (Affymetrix, Santa Clara, USA) analysis were as described previously (Kent et al., 2008) .
Quantitative PCR (qPCR)
qPCR was carried out in duplicate using 250ng aliquots of total RNA. The RNA was converted into cDNA using the ABI High-Capacity cDNA Archive Kit (Applied 
Luminex Analysis
Methodology for microsphere-antibody coupling and Luminex supernatant protein analysis for IL-6, IL-10, IP10 and TNFα is provided in the supplementary materials.
This procedure gave a range of 2.4-10,000 pg/ml and thus samples were diluted as appropriate in RPMI. All data points that were less than the lower limit of detection were given a value of half the lower limit (Laan et al., 2002) .
Statistical Analysis
Gene array data quality was assessed for homogeneity of quality control metrics by principal component analysis (PCA) using SIMCA-P+ software (Umetrics, Windsor, UK). Global analysis of gene expression was initially processed by normalising probe intensity data using Rosetta Resolver (Rosetta, Seattle, WA, USA) (Weng et al., 2006) prior to loading into SIMCA-P+ for visual assessment of key trends by gene RNA and protein data were analysed using a non-parametric ANOVA (Friedman's test with Dunn's post hoc analysis), followed by Wilcoxon matched-pairs signedranks one-tailed test to test for differences between treatments. Differences between groups (COPD patients and smokers) were assessed using Mann Whitney test.
Spearman's Rank Correlation Coefficient was used to assess the relationship between array and qPCR data. Tests were performed using GraphPad InStat Software (GraphPad Software Inc., San Diego, CA, USA).
RESULTS
MDM Cell Culture
Gene Expression Microarrays 58 inflammatory mediators that were significantly regulated in at least one experimental condition (LPS alone, or treatment with dexamethasone and / or SB706504) with a fold change >2 and a p< 0.01 were identified using IPA and manual gene cross referencing (table 2A-C). 23 genes were significantly up-regulated by LPS and inhibited by either dexamethasone, SB706504 and/or combined treatment (table 2A) . Four of these genes, CXCL1, 2, 3 and IL-8, were resistant to dexamethasone treatment but sensitive to the combined therapy (table 2A) . OMIM searches for chromosomal loci also found these genes to occupy the same locus;
4q12-q13. The heatmap in Fig 1 shows that combined treatment with dexamethasone and SB706504 caused the greatest degree of inhibition of these 23 genes (-8.90), which was more than the effect of dexamethasone alone (-3.39) or SB706504 alone (-2.04) when added together.
A further 23 genes were induced by LPS but were insensitive to any of the drug treatments (table 2B) . Ten genes were not induced by LPS, but were sensitive to dexamethasone and/or SB706504, and a further two genes were found to be suppressed by LPS treatment and induced by dexamethasone and/or SB706504 (table   2C) .
IPA analysis was applied to the 27 dexamethasone insensitive genes to create a network of inter-related genes based on a score-centric approach ( figure 2A ).
Amongst the most highly connected genes were IL-8, IL-1β, IL-18 and CCL5. The signalling pathways that were connected to GC insensitive genes were p38 MAPK, NFκB and AP-1. A similar approach was used for the 30 SB706504 insensitive genes (figure 2B); IL-8, IL-1β and IL-18 were again very highly connected to other drug insensitive genes, while the signalling pathways involved were p38 MAPK as expected and NFκB, and to a lesser extent PI3 kinase and JAK/STAT signalling.
qPCR
In LPS stimulated MDMs, treatment with dexamethasone or SB706504 alone significantly reduced IL-1β, IL-6, GM-CSF, TNFα and IL-8 mRNA levels (figure 3).
Greater inhibition with dexamethasone compared to SB706504 was observed for IL-1β, GM-CSF and TNFα mRNA levels. Co-treatment with dexamethasone and SB706504 caused significant further reductions in mRNA levels compared to treatment with dexamethasone or SB706504 alone for all five genes. The percentage reduction in expression levels of IL-1β, IL-6, GM-CSF, TNFα and IL-8 mRNA caused by dexamethasone are shown in table 3. This confirms the microarray findings that IL-8 and IL-1β were the most GC insensitive genes. The correlation between qPCR and array changes was extremely close and statistically significant (R=0.91,
p<0.0001).
Supernatant Proteins
In LPS stimulated MDMs, treatment with dexamethasone or SB706504 alone significantly reduced IL-6, IL-10, IP10 and TNFα protein levels measured by luminex (figure 4). ELISA measurements of IL-8 were numerically reduced by both of these drugs, but for SB706504 this difference did not reach statistical significance (figure This article has not been copyedited and formatted. The final version may differ from this version. Having observed that combined treatment with dexamethasone and SB706504 was greater than the individual components using the TLR2 and 4 agonist LPS, we then evaluated the same phenomenon using the specific TLR4 agonist UP-LPS in 7 COPD patients and 7 smokers (Fig 6) . and MDMs maximised the suppression of cytokine production, underscoring the possibility that this may be an effective anti-inflammatory strategy in COPD patients.
However, 27 inflammatory genes activated by LPS in COPD MDMs were insensitive to the effects of dexamethasone. Furthermore, 23 of these genes were insensitive to dexamethasone and SB706504, suggestive of a subset of "drug resistant"
inflammatory genes in COPD macrophages.
The numerical mean of the fold change suppression of gene expression caused by SB706504 alone (-2.04) and dexamethasone alone (-3.39) was less than the fold change suppression when these two drugs were administered together (-8.90 ). This is Further studies on using COPD macrophages are needed to address these potential mechanisms.
We identified 4 genes by microarray analysis that were GC resistant occupying the same locus on chromosome 4 (q12-q13); CXCL1 (GROα), CXCL2 (GROβ), CXCL3
(GROγ) and IL-8. Also, for 3 of these genes there was also no significant inhibition when SB706504 was used, but significant inhibition when both drugs were used. This suggests a synergistic interaction between these drugs, or "unlocking" of GC There is previous data from COPD AM that IL-8 is GC resistant (Cosio et al., 2004; Culpitt et al., 2003) . These previous studies add further weight to our findings that macrophage IL-8 production is GC insensitive. This probably has considerable therapeutic implications as IL-8 appears to play a key role in COPD pathophysiology; the levels of this neutrophil chemoattractant are raised in the lungs of COPD patients (Keatings et al., 1996) , and are associated with the rate of disease progression (Wilkinson et al., 2003) . Similarly, there is previous data that macrophage production of IL-8 is less sensitive to the effects of p38 inhibitors compared to other cytokines (Smith et al., 2006; Tudhope et al., 2008) , We also observed this phenomenon.
The chemokines CXCL1, 2 and 3 constitute the three members of the GRO family, GROα, GROβ and GROγ respectively. CXCL1 expression is increased in lung tissue We decided "a priori" to assess IL-1β, IL-6, GM-CSF, TNFα and IL-8 mRNA levels by qPCR. Using a criterion of p<0.05 in the qPCR analysis, we found that all of these genes were significantly suppressed by both drugs, but that IL-1β and IL-8 were the least sensitive genes. This confirmed the array analysis where IL-1β and IL-8 were both GC resistant. It should be noted that we used the criterion of p<0.01 and a fold change of >2 to define a significant change, as is common practice in array studies.
IPA analysis was used to generate a network of the possible relationships between GC insensitive genes, and the same approach was used for p38 MAPK inhibitor insensitive genes. This is an accepted approach for creating hypothetical gene networks utilising known mechanistic relationships between proteins and complexes (Juric et al., 2007; Li et al., 2007; Savli et al., 2008) . The IPA network allows genes that are "highly connected", and so more likely to be involved in inflammatory processes to be identified. This approach is "hypothesis generating", and we observed that IL-1β, IL-8, IL-18 and CCL5 were centrally involved in GC resistance. The
This article has not been copyedited and formatted. The final version may differ from this version. levels of all of these inflammatory mediators are raised in COPD patients (Costa et al., 2008; Imaoka et al., 2008; Keatings et al., 1996; Tomaki et al., 2007) , then these cytokines and chemokines could be considered to be key culprits in GC resistant inflammation in COPD patients.
IL-1β, IL-8 and IL-18 were also centrally involved in resistance to the effects of SB706504. These genes may be regulated by the same transcription factor, probably NFκB as suggested by both IPA networks. It should be stressed that these networks do not prove this mechanism, but provide the hypothesis that IL-1β, IL-8 and IL-18 are regulated by NFκB signalling which is both GC and p38 MAPK inhibitor resistant in COPD macrophages.
Our gene array study used MDMs as a surrogate for AM. There are similarities between MDMs and AM for studying the pharmacological effects of p38 MAPK inhibitors (Tudhope et al., 2008) . Accordingly, we postulate that the GC and p38
MAPK inhibitor resistant inflammatory genes that we observed in MDMs are also likely also to be resistant to the effects of these drugs in AM. We used a group of severe COPD patients for the gene array study. It would certainly be of interest to study whether the same findings were true in milder COPD patients, as well as controls, in order to study whether any of our findings are dependent on the presence or severity of COPD. alone on protein levels were generally similar. This suggests that SB706504 has significant post-transcriptional effects that influence the levels of secreted inflammatory proteins. Similarly, Birrell et al reported that the inhibitory effects of SB239063 and "compound 2" on AM IL-6 production were predominantly at the level of protein production rather than mRNA expression (Birrell et al., 2006) . The effects of p38 MAPK inhibitors on transcription may be concentration dependent, and which is worthy of further exploration.
LPS induced TNFα production was significantly suppressed by SB706504 in COPD patients and smokers, although inhibition was marginally greater in smokers compared to COPD patients (76.1% and 67.4%, p=0.047). SB706504 was also found to significantly inhibit TNFα production when stimulated by the specific TLR4 agonist UP-LPS, with similar inhibition in COPD patients compared to smokers. The sample size used was not specifically statistically powered to enable a sensitive comparison of drug effects between COPD patients and smokers. COPD AM are known to be less GC sensitive than those from controls (Culpitt et al., 2003) , and perhaps a larger study may elucidate any such difference when p38 MAPK inhibitors are used.
In summary, we have shown that the novel p38 MAPK inhibitor SB706504 has significant inhibitory effects on inflammatory mediator production from COPD macrophages. Importantly, we provide evidence that using this p38 MAPK inhibitor with GC can provide enhanced anti-inflammatory effects. However, we also demonstrate a subset of macrophage inflammatory genes that are resistant to the effects of these anti-inflammatory drugs, and some of these are known to be involved in the pathophysiology of COPD. Targeting these genes with different antiinflammatory interventions may be needed.
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